Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15652315 | 0.90 | LMNA (0.55) | LMNAALDH1A1KMT2AHRH3SMN1; SMN2 | |
| SCHEMBL3243026 | 0.86 | ATM (0.61) | LMNAALDH1A1KMT2AHRH3SMN1; SMN2 | |
| SCHEMBL20665487 | 0.86 | ALDH1A1 (0.55) | LMNAALDH1A1KMT2AHRH3SMN1; SMN2 | |
| SCHEMBL8186898 | 0.84 | ALDH1A1 (0.74) | LMNAALDH1A1KMT2ASMN1; SMN2KDM4E | |
| SCHEMBL3916831 | 0.83 | HRH3 (0.76) | LMNAALDH1A1KMT2AHRH3SMN1; SMN2 | |
| SCHEMBL19002248 | 0.82 | POLB (0.64) | LMNAALDH1A1KMT2ASMN1; SMN2HTT | |
| SCHEMBL188249 | 0.82 | KMT2A (0.54) | LMNAALDH1A1KMT2AHRH3SMN1; SMN2 | |
| SCHEMBL265853 | 0.81 | VEGFA (0.55) | LMNAALDH1A1KMT2AHRH3SMN1; SMN2 | |
| SCHEMBL5031225 | 0.81 | LMNA (0.59) | LMNAALDH1A1KMT2AHRH3SMN1; SMN2 | |
| SCHEMBL18997537 | 0.80 | ALDH1A1 (0.49) | LMNAALDH1A1KMT2AHRH3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | LMNA 4499/4885ALDH1A1 1119/4885KMT2A 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.